Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach

Journal of Medicinal Chemistry

Volumn 46, Issue 17, 2003, Pages 3631-3643

  Korolev, Dmitry ^a   Balakin, Konstantin V ^b   Nikolsky, Yuri ^b   Kirillov, Eugene ^a   Ivanenkov, Yan A ^b   Savchuk, Nikolay P ^b   Ivashchenko, Andrey A ^b   Nikolskaya, Tatiana ^a  

^a GeneGo bioinformatics software Inc   (United States)

^b CHEMDIV INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; XENOBIOTIC AGENT;

ALGORITHM; ARTICLE; DRUG METABOLISM; DRUG TRANSFORMATION; LEARNING; MACHINE; PHYSICAL CHEMISTRY; REACTION OPTIMIZATION; XENOBIOTIC METABOLISM;

ALGORITHMS; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; HUMANS; ISOENZYMES; NEURAL NETWORKS (COMPUTER); PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; XENOBIOTICS;

EID: 0043234176     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030102a     Document Type: Article

References (48)

1. Smith, R. V.; Erhardt, P. W.; Leslie, S. W. Microsomal O-Demethylation, N-Demethylation and Aromatic Hydroxylation in the Presence of Bisulfite and Dithiothreitol. Res. Commun. Chem. Path. Pharmacol. 1975, 12, 181-184.
2. Bodor, N. Retrometabolic Approaches for Drug Design and Targeting. Pharmazie 1997, 52, 491-499.
3. (a) Darvas, F. MetabolExpert: an Expert System for Predicting the Metabolism of Substances. InQSAR in Environmental Toxicology II; Kaiser, K. L., Ed.; Reidel Co.: Dordrecht, 1987; pp 71-81.
4. (b) Darvas, F.; Marokházi, S.; Kormos, P.; Kulkarni, G.; Kalász, H.; Papp, A. MetabolExpert: Its Use in Metabolism Research and in Combinatorial Chemistry. In Drug Metabolism. Databases and High-Throughput Testing During Drug Design and Development; Erhardt, P. W., Ed.; Blackwell Science Ltd., 1999; pp 237-270.
5. (a) Klopman, G.; Dimayuga, M.; Talafous, J. META. 1. A Program for the Evaluation of Metabolic Transformations of Chemicals. J. Chem. Inf. Comput. Sci. 1994, 34, 1320-1325.
6. (b) Klopman, G.; Tu, M. META: A Program for the Prediction of the Products of Mammal Metabolism of Xenobiotics. In Drug Metabolism. Databases and High-Throughput Testing During Drug Design and Development; Erhardt, P. W., Ed. ; Blackwell Science Ltd., 1999; pp 271-276.
7. Darvas, F. Predicting Metabolic Pathways by Logic Program ming. J. Mol. Graphics 1988, 6, 80-86.
8. Snyder, R. W.; Grethe, G. Metabolite. In Drug Metabolism. Databases and High-Throughput Testing During Drug Design and Development; Erhardt, P. W., Ed. ; Blackwell Science Ltd., 1999; pp 277-280.
9. Mulder, G. Conjugation Reactions in Drug Metabolism; Taylor & Francis, London, 1990.
10. Hayashi, S.; Watanabe, J.; Kawajiri, K. Genetic Polymorphism in the 5′-Flanking Region Change Transcriptional Regulation of the Human Cytochrome P450IIE1 Gene. J. Biochem. (Tokyo) 1991, 110, 559-565.
11. Kato, S.; Onda, M.; Matsukura, N.; Tokunaga, A.; Tajiri, T.; Kim, D. Y.; Tsuruta, H.; Matsuda, N.; Yamashita, K.; Shields, P. G. Cytochrome P4502E1 (CYP2E1) Genetic Polymorphism in a Case-Control Study of Gastric Cancer and Liver Disease. Pharmacogenetics 1995, 5, S141-S144.
12. (a) Ioannides, C.; Parke, D. V. Cytochromes P450: Metabolic and Toxicological Aspects. CRC Press: New York, 1996.
13. (b) Lechner, C. Cytochrome P450: Biochemistry, Biophysics and Molecular Biology; John Libbey Eurotext, Montrouge, France, 1995.
14. Commercially available from GeneGo, Inc. (New Buffalo, USA). URL: http://www.genego.com/.
15. Accelrys, Inc., 2000. URL: http://www.accelrys.com/.
16. Chemical Diversity Labs, Inc., 2002. URL: http://www.chemdiv.com/.
17. Raevsky, O. A.; Trepalin, S. V.; Trepalina, H. P.; Gerasimenko, V. A.; Raevskaya, O. E. SLIPPER-2001 - Software for Predicting Molecular Properties on the Basis of Physicochemical Descriptors and Structural Similarity. J. Chem. Inf. Comput. Sci. 2002, 42, 540-549.
18. NeuroDimension, Inc., 2001. URL: http://www.nd.com/.
19. Gonzales, F. The Molecular Biology of Cytochrome P450s. Pharmacol. Rev. 1989, 40, 243-288.
20. Koymans, L.; Kelder, G.; Te, J.; Vermeulen, N. Cytochromes P450: Their Active-Site Structure and Mechanism of Oxidation. Drug Metab. Rev. 1993, 25, 325-327.
21. Estabrook, R. W. Cytochrome P450: from a Single Protein to a Family of Proteins - with some personal reflections. In Cytochromes P450: Metabolic and Toxicological Aspects; Ionnides and Parke, Eds.; CRC Press: New York, 1996; pp 4-28.
22. Nebert, D. Multiple Forms of Inducible Drug-Metabolizing Enzymes: a Reasonable Mechanism by Which Any Organism Can Cope with Adversity. Mol. Cell. Biochem. 1979, 27, 27-46.
23. (a) de Groot, M. J.; Bijloo, G. J.; Martens, B. J.; van Acker, F. A. A.; Vermeulen, N. P. E. A Refined Substrate Model for Human Cytochrome P450 2D6. Chem. Res. Toxicol. 1997, 10, 41-48.
24. (b) de Groot, M. J.; Ackland, M. J.; Horne, V. A.; Alex, A. A.; Jones, B. C. Novel Approach To Predicting P450-Mediated Drug Metabolism: Development of a Combined Protein and Pharmacophore Model for CYP2D6. J. Med. Chem. 1999, 42, 1515-1524.
25. (c) Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three- and Four-dimensional Quantitative Structure-Activity Relationship Analyses of Cytochrome P-450 3A4 Iinhibitors. J. Pharmacol. Exp. Ther. 1999, 290, 429-438.
26. Higgins, L.; Korzekwa, K. R.; Rao, S.; Shou, M.; Jones, J. P. An Assessment of the Reaction Energetics for Cytochrome P450-mediated Reactions. Arch. Biochem. Biophys. 2001, 385, 220-230.
27. (a) Ajay, A.; Walters, W. P.; Murcko, M. A. Can We Learn to Distinguish between "Drug-Like" and "Nondrug-Like" Molecules? J. Med. Chem. 1998, 41, 3314-3324.
28. (b) Ajay; Bemis, G. W.; Murcko, M. A. Designing Libraries with CNS Activity. J. Med. Chem. 1999, 42, 4942-4951.
29. (c) Sadowski, J.; Kubinyi, H. A Scoring Scheme for Discriminating between Drugs and Nondrugs. J. Med. Chem. 1998, 41, 3325-3329.
30. Balakin, K. V.; Tkachenko, S. E.; Lang, S. A.; Okun, I.; Ivashchenko, A. I.; Savchuk, N. P. Property-Based Design of GPCR-Targeted Library. J. Chem. Inf. Comput. Sci. 2002, 42, 1332-1342.
31. Anzali, S.; Gasteiger, J.; Holzgrabe, U.; Polanski, J.; Sadowski, J.; Teckentrup, A.; Wagener, M. The Use of Self-Organizing Neural Networks in Drug Design. In 3D QSAR im Drug Design - Volume 2; Kubinyi, H.; Folkers, G.; Martin, Y. C., Eds.; Kluwer/ESCOM, Dordrecht, NL, 1998; pp 273-299.
32. Bauknecht, H.; Zell, A.; Bayer, H.; Levi, P.; Wagener, M.; Sadowski, J.; Gasteiger, J. Locating Biologically Active Compounds in Medium-Sized Heterogeneous Datasets by Topological Autocorrelation Vectors: Dopamine and Benzodiazepine Agonists. J. Chem. Inf. Comput. Sci. 1996, 36, 1205-1213.
33. Anzali, S.; Barnickel, G.; Krug, M.; Sadowski, J.; Wagener, M.; Gasteiger, J.; Polanski, J. The Comparison of Geometric and Electronic Properties of Molecular Surfaces by Neural Networks: Application to the Analysis of Corticosteroid Binding Globulin Activity of Steroids. J. Comput.-Aid. Mol. Des. 1996, 10, 521-534.
34. Brüstle, M.; Beck, B.; Schindler, T.; King, W.; Mitchell, T.; Clark, T. Descriptors, Physical Properties, and Drug-Likeness. J. Med. Chem. 2002, 45, 3345-3355.
35. Jolliffe, I. T. Principal Component Analysis; Springer-Verlag: New York, 1986.
36. (a) Guttmann, L. Some Necessary Conditions for Common Factor Analysis. Psychometrika 1954, 19, 149-162.
37. (b) Kaiser, H. F.; Dickmann, K. Analytic Determination of Common Factors. Am. Psychol. 1959, 14, 425-439.
38. (a) Catell, R. B.; Vogelmann, S. A Comprehensive Trial of the Scree and KG-Criteria for Determining the Number of Factors. Multi. Behav. Res. 1977, 12, 289-325.
39. (b) Catell, R. B. The Scree Test for the Number of Factors. Multi. Behav. Res. 1966, 1, 245-276.
40. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; Macintyre, F.; Rance, D. J.; Wastall, P. The Prediction of Human Pharmacokinetic Parameters from Preclinical and in vitro Metabolism Data. J. Pharm. Exp. Ther. 1997, 283, 46-58.
41. Obach, R. S. Nonspecific Binding to Microsomes: Impact on Scale-up of in vitro Intrinsic Clearance to Hepatic Clearance as Assessed Through Examination of Warfarin, Imipramine and Propranolol. Drug Metab. Dispos. 1997, 25, 1359-1369.
42. Spatzenegger, M.; Jaeger, W. Clinical Importance of Hepatic Cytochrome P450 in Drug Metabolism. Drug Metab. Rev. 1995, 27, 397-417.
43. (a) Chang, Y.-T.; Stiffelman, O. B.; Vakser, I. A.; Loew, G. H.; Bridges, A.; Waskell, L. Construction of a 3D Model of Cytochrome P4502B4. Prot. Engin. 1997, 10, 119-129.
44. (b) Chang, Y.-T.; Loew, G. H. Computer Modeling of 3D Structures of Cytochrome P450s. Biochimie 1996, 78, 771-779.
45. Gonzales, F.; Gelboin, H. Human Cytochromes P450: Evolution and cDNA-directed Expression. Environ. Health Persp. 1992, 98, 81-85.
46. Gonzales, F. Human Cytochromes P450: Problems and Prospects. Trends Pharm. Sci. 1992, 13, 346-352.
47. Rodrigues, A. D. Use of in vitro Metabolism Studies in Drug Development: an Industrial Perspective. Biochem. Pharmacol. 1994, 48, 2147-2156.
48. Darvas, F.; Dormán, G.; Papp, A. Diversity Measures for Enhancing ADME Admissibility of Combinatorial Libraries. J. Chem. Inf. Comput. Sci. 2000, 40, 314-322.